Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Filings indexed 968 across all filing types
Latest filing 2026-05-07 Regulatory Filings
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
BioSenic SA_Information on shareholders' rights AGM_FR_Final(1577995.2).pdf
Regulatory Filings
2026-05-07 French
BioSenic SA_proxy AGM_FR_Final(1577975.2).pdf
Regulatory Filings
2026-05-07 French
BIOS_PR AGM 2026_FR_final(1574246.1).pdf
Regulatory Filings
2026-05-07 French
BioSenic SA_Convening notice AGM_FR_Final(1574100.2).pdf
Regulatory Filings
2026-05-07 French
BioSenic Rapport annuel 2025.pdf
Annual Report Classification · 100% confidence The document is titled 'Rapport Annuel 2025' which translates to 'Annual Report 2025'. It contains detailed sections typical of an annual report such as general information, management report, organizational structure, governance, related party transactions, shareholders, statutory accounts, and auditor's report. It references compliance with Belgian corporate law and financial regulations, includes a letter to shareholders, company strategy, and financial restructuring details. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. Therefore, this document is the official yearly report covering company activity and full financial performance, fitting the definition of an Annual Report (10-K).
2026-04-30 French
BioSenic Rapport annuel 2025FR.xhtml
Annual Report Classification · 100% confidence The document is titled 'BioSenic Rapport annuel 2025' which translates to 'BioSenic Annual Report 2025'. It contains a detailed table of contents including general information, management report, organizational structure, corporate governance, related party transactions, shareholders, statutory accounts, and auditor's report. The text references compliance with Belgian corporate law and financial reporting requirements, mentions audited annual financial statements, and includes a letter to shareholders discussing the company's strategy and financial restructuring. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. These characteristics clearly identify the document as a full Annual Report covering the company's activities and financial performance for the fiscal year ending December 31, 2025. FY 2025
2026-04-30 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.